)
Visual21 Nov 2025
Data center suppliers
Crinetics Pharmaceuticals (CRNX) investor relations material
Crinetics Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
FDA approved PALSONIFY (paltusotine) for acromegaly in September 2025, marking a transition to commercial-stage with strong early uptake and positive reimbursement trends; European review ongoing with potential EMA decision in H1 2026.
Early launch progress includes prescriptions from both community and academic prescribers, with 95% from switch patients and positive feedback from patients, physicians, and payers.
The company is executing a three-phase launch strategy: initial focus on switch patients, then re-engaging lapsed patients, and finally improving diagnosis rates.
Pipeline momentum continues with five advancing clinical trials, including late-stage programs for atumelnant in CAH and Cushing's, and new candidates for neuroendocrine tumors.
Cash runway projected into 2029, supporting commercialization and pipeline advancement.
Financial highlights
Q3 2025 revenue was $0.1 million, all from licensing agreements; no product revenue recognized in Q3 due to timing of approval.
R&D expenses were $90.5 million in Q3 2025, up from $80.3 million in Q2 and $61.9 million in Q3 2024, reflecting increased clinical activity.
SG&A expenses were $52.3 million in Q3 2025, up from $49.8 million in Q2 and $25.9 million in Q3 2024, driven by launch investments and headcount growth.
Net loss for Q3 2025 was $130.1 million, up 69% year-over-year; net loss per share was $1.38.
Ended Q3 2025 with $1.1 billion in cash, cash equivalents, and investments.
Outlook and guidance
Maintains 2025 net cash used in operations guidance of $340–370 million.
Cash position expected to fund operations into 2029, supporting commercialization and pipeline advancement.
Multiple late-stage clinical milestones anticipated in Q4 2025 and early 2026, including Phase 3 trial initiations and data readouts.
Launch metrics, including revenue, new patient starts, and prescriber numbers, will be provided after a full quarter in Q1 2026.
Palsonify reimbursement rate: Elaborate on 50%?
TSHR/SST3 program delays: What are the impacts?
Palsonify product sales: When will revenue appear?
PALSONIFY: Community prescriber uptake strategy
Graves' disease tox findings: Timeline impact
Strategy for returning lost acromegaly patients to care
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Crinetics Pharmaceuticals earnings date
Q4 202526 Feb, 2026
Next Crinetics Pharmaceuticals earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Crinetics Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that specializes in the development of novel therapeutics targeting peptide hormone receptors. Their focus is on the treatment of rare endocrine disorders and endocrine-related tumors. The company’s leading product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist. It is in advanced clinical trials for conditions such as acromegaly, carcinoid syndrome, and nonfunctional neuroendocrine tumors. Additionally, Crinetics Pharmaceuticals is developing other drug candidates for conditions like congenital hyperinsulinism and Cushing's disease. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage